Monument Therapeutics announces the start of its first clinical study for novel treatment for neuroinflammation

Manchester, UK, June 13, 2022: Monument Therapeutics, a stratified medicine company, today announced that their first-in-human Phase I study of MT1980, a novel formulation of an on-market anti-inflammatory compound, has commenced. MT1980 has been...

Proveca enters an exclusive agreement with Mawdsley Brooks Brazil

Proveca has entered an exclusive agreement with Mawdsley Brooks Brazil, part of global pharmaceutical services provider Mawdsleys, to commercialise and distribute Sialanar® in Brazil. Under the terms of the agreement, Mawdsley Brooks Brazil w...

Rinicare’s SAFE falls reduction technology granted new UK patent

SAFE has been designed to reduce the burden on overstretched clinicians and care home staff by alerting them to pending falls events. A recently published white paper projected that falls amongst older people will increase by 3.9% a year mean...

Trial to assess Acute Kidney Injury risk prediction technology starts at MFT

A pioneering clinical trial of new technology to predict the risk of patients developing Acute Kidney Injury (AKI) has begun at Manchester University NHS Foundation Trust (MFT). The STABILITY UO (Urine Output) clinical risk prediction t...

NIHR backed AI care planning network goes live

English healthcare providers are now able to join a network that uses crowd sourced data to shape care plans. Healum, an artificial intelligence-based App, uses data that patients have chosen to share in order to personalise care recommendations a...

From our portfolio

Manchester Imaging

Digital Healthcare Technology

viewview our portfolio

Our Team

Nick Wright


view complete team

Contact us

Tel: 01625 344300